Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH-2007-1.2-2;HEALTH-2007-2.4.1-7 | Award Amount: 3.25M | Year: 2008
The overall objective of this proposal is the development of one or more nanosystems loaded with Foscan and conjugated to cancer cell specific ligands for improving the efficacy and selectivity of photodynamic therapy (PDT) and optimise a fluorescence-based tumour imaging approach. At present, PDT with Foscan can be very effective but is not selective because Foscan accumulates in the tumour tissue as well as in healthy ones. A great improvement of the therapy can only come from the availability of a carrier able to seek cancer cells and deliver Foscan selectively to them. Three types of nanosystems, namely, liposomes, silica nanoparticles or poly(lactide-co-glycolide) copolymer nanoparticles, have been selected as potential nanocarriers for the selective delivery of Foscan. The selection was mainly based on the different chemical nature of these systems, which can affect biocompatibility. During the first part of the project each type of nanosystem will be optimised through in vitro and in vivo tests and leader nanocarriers will be selected and conjugated to cancer cells specific ligands for increasing the selective delivery of Foscan. The ligands we will use (folic acid, EGF, and antibodies) for targeting the nanosystems find their corresponding receptor over-expressed on the surface of cancer cells, therefore allowing a selective delivery of drugs in these cells. In vitro and in vivo investigations will be carried to demonstrate the validity of our approach and deliver, at project conclusion, a final product which can then be tested clinically. Because of the red fluorescence emitted by Foscan, once it is selectively accumulated in cancer cells fluorescence based technique can be used for tumour imaging and diagnosis. Therefore we expect to develop a Foscan loaded nanosystem/s which can be used for improving both therapeutic and tumour imaging approaches.
News Article | November 23, 2016
This report studies Medical Laser Systems in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering AngioDynamics Inc. Bausch & Lomb Incorporated BIOLASE Inc. Biolitec AG Carl Zeiss Meditec AG Coherent Inc. Palomar Medical Technologies Inc. Nidek Co Ltd. Topcon Corporation Ellex Medical Lasers Limited Novartis AG View Full Report With Complete TOC, List Of Figure and Table: http://globalqyresearch.com/global-medical-laser-systems-market-research-report-2016 Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Medical Laser Systems in these regions, from 2011 to 2021 (forecast), like North America Europe China Japan Southeast Asia India Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into Surgical Lasers Aesthetic Lasers Ophthalmic Lasers Diagnostic Lasers Split by application, this report focuses on consumption, market share and growth rate of Medical Laser Systems in each application, can be divided into Medicine Biology Others Global Medical Laser Systems Market Research Report 2016 1 Medical Laser Systems Market Overview 1.1 Product Overview and Scope of Medical Laser Systems 1.2 Medical Laser Systems Segment by Type 1.2.1 Global Production Market Share of Medical Laser Systems by Type in 2015 1.2.2 Surgical Lasers 1.2.3 Aesthetic Lasers 1.2.4 Ophthalmic Lasers 1.2.5 Diagnostic Lasers 1.3 Medical Laser Systems Segment by Application 1.3.1 Medical Laser Systems Consumption Market Share by Application in 2015 1.3.2 Medicine 1.3.3 Biology 1.3.4 Others 1.4 Medical Laser Systems Market by Region 1.4.1 North America Status and Prospect (2011-2021) 1.4.2 Europe Status and Prospect (2011-2021) 1.4.3 China Status and Prospect (2011-2021) 1.4.4 Japan Status and Prospect (2011-2021) 1.4.5 Southeast Asia Status and Prospect (2011-2021) 1.4.6 India Status and Prospect (2011-2021) 1.5 Global Market Size (Value) of Medical Laser Systems (2011-2021) 7 Global Medical Laser Systems Manufacturers Profiles/Analysis 7.1 AngioDynamics Inc. 7.1.1 Company Basic Information, Manufacturing Base and Its Competitors 7.1.2 Medical Laser Systems Product Type, Application and Specification 188.8.131.52 Type I 184.108.40.206 Type II 7.1.3 AngioDynamics Inc. Medical Laser Systems Production, Revenue, Price and Gross Margin (2015 and 2016) 7.1.4 Main Business/Business Overview 7.2 Bausch & Lomb Incorporated 7.2.1 Company Basic Information, Manufacturing Base and Its Competitors 7.2.2 Medical Laser Systems Product Type, Application and Specification 220.127.116.11 Type I 18.104.22.168 Type II 7.2.3 Bausch & Lomb Incorporated Medical Laser Systems Production, Revenue, Price and Gross Margin (2015 and 2016) 7.2.4 Main Business/Business Overview 7.3 BIOLASE Inc. 7.3.1 Company Basic Information, Manufacturing Base and Its Competitors 7.3.2 Medical Laser Systems Product Type, Application and Specification 22.214.171.124 Type I 126.96.36.199 Type II 7.3.3 BIOLASE Inc. Medical Laser Systems Production, Revenue, Price and Gross Margin (2015 and 2016) 7.3.4 Main Business/Business Overview 7.4 Biolitec AG 7.4.1 Company Basic Information, Manufacturing Base and Its Competitors 7.4.2 Medical Laser Systems Product Type, Application and Specification 188.8.131.52 Type I 184.108.40.206 Type II 7.4.3 Biolitec AG Medical Laser Systems Production, Revenue, Price and Gross Margin (2015 and 2016) 7.4.4 Main Business/Business Overview 7.5 Carl Zeiss Meditec AG 7.5.1 Company Basic Information, Manufacturing Base and Its Competitors 7.5.2 Medical Laser Systems Product Type, Application and Specification 220.127.116.11 Type I 18.104.22.168 Type II 7.5.3 Carl Zeiss Meditec AG Medical Laser Systems Production, Revenue, Price and Gross Margin (2015 and 2016) 7.5.4 Main Business/Business Overview 7.6 Coherent Inc. 7.6.1 Company Basic Information, Manufacturing Base and Its Competitors 7.6.2 Medical Laser Systems Product Type, Application and Specification 22.214.171.124 Type I 126.96.36.199 Type II 7.6.3 Coherent Inc. Medical Laser Systems Production, Revenue, Price and Gross Margin (2015 and 2016) 7.6.4 Main Business/Business Overview 7.7 Palomar Medical Technologies Inc. 7.7.1 Company Basic Information, Manufacturing Base and Its Competitors 7.7.2 Medical Laser Systems Product Type, Application and Specification 188.8.131.52 Type I 184.108.40.206 Type II 7.7.3 Palomar Medical Technologies Inc. Medical Laser Systems Production, Revenue, Price and Gross Margin (2015 and 2016) 7.7.4 Main Business/Business Overview 7.8 Nidek Co Ltd. 7.8.1 Company Basic Information, Manufacturing Base and Its Competitors 7.8.2 Medical Laser Systems Product Type, Application and Specification 220.127.116.11 Type I 18.104.22.168 Type II 7.8.3 Nidek Co Ltd. Medical Laser Systems Production, Revenue, Price and Gross Margin (2015 and 2016) 7.8.4 Main Business/Business Overview 7.9 Topcon Corporation 7.9.1 Company Basic Information, Manufacturing Base and Its Competitors 7.9.2 Medical Laser Systems Product Type, Application and Specification 22.214.171.124 Type I 126.96.36.199 Type II 7.9.3 Topcon Corporation Medical Laser Systems Production, Revenue, Price and Gross Margin (2015 and 2016) 7.9.4 Main Business/Business Overview 7.10 Ellex Medical Lasers Limited 7.10.1 Company Basic Information, Manufacturing Base and Its Competitors 7.10.2 Medical Laser Systems Product Type, Application and Specification 188.8.131.52 Type I 184.108.40.206 Type II 7.10.3 Ellex Medical Lasers Limited Medical Laser Systems Production, Revenue, Price and Gross Margin (2015 and 2016) 7.10.4 Main Business/Business Overview 7.11 Novartis AG Global QYResearch ( http://globalqyresearch.com/ ) is the one spot destination for all your research needs. Global QYResearch holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making purchase decision by understanding their requirements and suggesting best possible collection matching their needs.
Yang K.,Friedrich - Schiller University of Jena |
Gitter B.,Biolitec AG |
Ruger R.,Friedrich - Schiller University of Jena |
Albrecht V.,Biolitec AG |
And 2 more authors.
Photochemistry and Photobiology | Year: 2012
Photodynamic inactivation (PDI) of bacteria is a promising approach for combating the increasing emergence of antibiotic resistance in pathogenic bacteria. To further improve the PDI efficiency on bacteria, a bacteria-targeting liposomal formulation was investigated. A generation II photosensitizer (temoporfin) was incorporated into liposomes, followed by conjugation with a specific lectin (wheat germ agglutinin, WGA) on the liposomal surface. WGA was successfully coupled to temoporfin-loaded liposomes using an activated phospholipid containing N-hydroxylsuccinimide residue. Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa were selected to evaluate the WGA modified liposomes in terms of bacteria targeted delivery and in vitro PDI test. Fluorescence microscopy revealed that temoporfin was delivered to both kinds of bacteria, while flow cytometry demonstrated that WGA- modified liposomes delivered more temoporfin to bacteria compared to nonmodified liposomes. Consequently, the WGA- modified liposomes eradicated all MRSA and significantly enhanced the PDI of P. aeruginosa. In conclusion, the WGA- modified liposomes are a promising formulation for bacteria targeted delivery of temoporfin and for improving the PDI efficiency of temoporfin on both Gram-positive and Gram-negative bacterial cells. The surface of temoporfin-loaded liposomes was modified with a bacteria-targeting ligand, wheat germ agglutinin, to prepare bacteria-targeting liposomes, which bind to bacteria and consequently increase the delivery of temoporfin to bacteria. After light illumination, the photosensitizers (temoporfin) generate reactive oxygen species, resulting in photodynamic inactivation of bacteria. © 2011 The American Society of Photobiology.
Klesing J.,University of Duisburg - Essen |
Wiehe A.,Biolitec AG |
Gitter B.,Biolitec AG |
Grafe S.,Biolitec AG |
Epple M.,University of Duisburg - Essen
Journal of Materials Science: Materials in Medicine | Year: 2010
The charge of nanoparticles influences their ability to pass through the cellular membrane, and a positive charge should be beneficial. The negative charge of calcium phosphate nanoparticles with an inner shell of carboxymethyl cellulose (CMC) was reversed by adding an outer shell of poly(ethyleneimine) (PEI) into which the photoactive dye 5,10,15,20-tetrakis(3-hydroxyphenyl)- porphyrin (mTHPP) was loaded. The aqueous dispersion of the nanoparticles was used for photodynamic therapy with HT29 cells (human colon adenocarcinoma cells), HIG-82 cells (rabbit synoviocytes), and J774A.1 cells (murine macrophages). A high photodynamic activity (killing) together with a very low dark toxicity was observed for HIG-82 and for J774.1 cells at 2 μM dye concentration. The killing efficiency was equivalent to the pure photoactive dye that, however, needs to be administered in alcoholic solution. © 2009 Springer Science+Business Media, LLC.
Dragicevic-Curic N.,Friedrich - Schiller University of Jena |
Grafe S.,Biolitec AG |
Gitter B.,Biolitec AG |
Fahr A.,Friedrich - Schiller University of Jena
Journal of Photochemistry and Photobiology B: Biology | Year: 2010
In the case of cutaneous malignant or non-malignant diseases, topical photodynamic therapy (PDT) with a temoporfin (mTHPC)-containing formulation would be advantageous. Unfortunately, mTHPC is a highly hydrophobic drug with low percutaneous absorption and novel mTHPC-loaded invasomes for enhanced skin delivery were developed. The purpose of this study was to investigate photodynamic efficacy of mTHPC-loaded invasomes in vitro in two cell lines, i.e. the human colorectal tumour cell line HT29 and the epidermoid tumour cell line A431. Invasomes are vesicles containing besides phospholipids a mixture of terpenes or only one terpene and ethanol. Dark toxicity, phototoxicity and intracellular localization of mTHPC were studied. Laser scanning microscopy indicated perinuclear localization of mTHPC. Results revealed that mTHPC-invasomes and mTHPC-ethanolic solution used at a 2μM mTHPC-concentration and photoirradiation at 20J/cm2 were able to reduce survival of HT29 cells and especially of A431 cells, being more sensitive to PDT. In contrast to HT29 cells, where there was not a significant difference between cytotoxicity of mTHPC-ethanolic solution and mTHPC-invasomes, in A431 cells mTHPC-invasomes were more cytotoxic. Survival of about 16% of A431 cells treated with mTHPC-invasomes is very promising, since it demonstrates invasomes' potential to be used in topical PDT of cutaneous malignant diseases. © 2010 Elsevier B.V.
News Article | December 5, 2016
Photorejuvenation is a popular skin treatment method. Photorejuvenation equipment comprises various light emitting diodes (LED), lasers, intense pulsed light and other thermal methods for the skin treatment. The use of photorejuvenation therapy is very extensive and often used as an alternative for expensive skin treatments such as plastic surgery. Photorejuvenation based skin treatments are used widely in various skin diseases such as acne, acne scars, rosacea, matted telangiectasia, lentigines cherry, angioma and spider angioma, red or blue facial and leg veins. It is also used in application such as birthmark and tattoo removal, and hair removal Photorejuvenation technology uses high intensity light emitting device (such as laser and LED). Photorejuvenation therapy is useful in enhancing skin quality, removal of fine wrinkles from the facial skin, removal of skin marks and spots, and some of the other treatment such as age spots, sun spots, and freckles. On the basis of various technology of the photorejuvenation the global photorejuvenation equipment market can be segmented in three broad categories namely mechanical (such as LED and laser), thermal (such as thermage) and chemical (such as chemical peels). Cost effectiveness of photorejuvenation over its counterparts such as plastic surgery is one of the major drivers of the market. In addition photorejuvenation treatments take little or no downtime and cause very few side effects compare to other skin treatment methods. More over the growing inspiration to look young and charming among the aging population is further driving the global photorejuvenation equipment market. Suspicion of skin cancer around the treatment area, speculation regarding hypersensitivity to light and some time unrealistic expectations of consumers, are acting as some of the major challenges for the global photo rejuvenation equipment market. North America is the largest market for photorejuvenation equipment in 2013 followed by Europe and Asia Pacific. Asia Pacific is one of the fasted growing markets of photorejuvenation equipment market attributed to the growing demand from Japan, China and South Korea. The photorejuvenation treatment equipment market is still in nascent stage in Asia Pacific and with increasing purchasing power of the consumers coupled with rising healthcare industries it is expected that market will grow at healthy rate in coming years. Request for Sample and Table of content Report @ : http://www.persistencemarketresearch.com/samples/3249 Some of the leading companies operating in global photorejuvenation Equipment Market include, Abbott Medical Optics, AESCULIGHT LLC, Alcon Inc., Biolitec AG., Candela Corp., Deka Laser, Dornier Medtech GMBH, Erchonia medical, LISA laser products, Lumenis Ltd., Nidek company ltd., and Vascular solution Inc.
Low K.,Fraunhofer Institute for Biomedical Engineering |
Knobloch T.,Goethe University Frankfurt |
Wagner S.,Fraunhofer Institute for Biomedical Engineering |
Wiehe A.,Biolitec AG |
And 3 more authors.
Nanotechnology | Year: 2011
The second generation photosensitizer mTHPC was approved by the European Medicines Agency (EMA) for the palliative treatment of advanced head and neck cancer in October 2001. It is known that mTHPC possesses a significant phototoxicity against a variety of human cancer cells invitro but also exhibits dark toxicity and can cause adverse effects (especially skin photosensitization). Due to its poor water solubility, the administration of hydrophobic photosensitizer still presents several difficulties. To overcome the administration problems, the use of nanoparticles as drug carrier systems is much investigated. Nanoparticles based on poly(lactic-co-glycolic acid) (PLGA) have been extensively studied as delivery systems into tumours due to their biocompatibility and biodegradability. The goal of this study was the comparison of free mTHPC and mTHPC-loaded PLGA nanoparticles concerning cytotoxicity and intracellular accumulation in human colon carcinoma cells (HT29). The nanoparticles delivered the photosensitizer to the colon carcinoma cells and enabled drug release without losing its activity. The cytotoxicity assays showed a time-and concentration-dependent decrease in cell proliferation and viability after illumination. However, first and foremost mTHPC lost its dark toxic effects using the PLGA nanoparticles as a drug carrier system. Therefore, PLGA nanoparticles are a promising drug carrier system for the hydrophobic photosensitizer mTHPC. © 2011 IOP Publishing Ltd.
Aicher D.,University of Leipzig |
Wiehe A.,Free University of Berlin |
Wiehe A.,Biolitec AG |
Stark C.B.W.,University of Leipzig
Synlett | Year: 2010
The trichloroacetimidate method has been utilized for the glycosylation of porphyrins. The corresponding glycoconjugates were obtained rapidly, in high yields, and excellent purity. A three-step sequence using well-matched (Lewis) acids was found to be highly effective and reliable. © Georg Thieme Verlag Stuttgart New York.
Schastak S.,University of Leipzig |
Ziganshyna S.,University of Leipzig |
Gitter B.,Biolitec AG |
Wiedemann P.,University of Leipzig |
Claudepierre T.,University of Leipzig
PLoS ONE | Year: 2010
The worldwide rise in the rates of antibiotic resistance of bacteria underlines the need for alternative antibacterial agents. A promising approach to kill antibiotic-resistant bacteria uses light in combination with a photosensitizer to induce a phototoxic reaction. Concentrations of 1, 10 and 100mM of tetrahydroporphyrin-tetratosylat (THPTS) and different incubation times (30, 90 and 180min) were used to measure photodynamic efficiency against two Gram-positive strains of S.aureus (MSSA and MRSA), and two Gram-negative strains of E.coli and P.aeruginosa. We found that phototoxicity of the drug is independent of the antibiotic resistance pattern when incubated in PBS for the investigated strains. Also, an incubation with 100μM THPTS followed by illumination, yielded a 6lg (≥99.999%) decrease in the viable numbers of all bacteria strains tested, indicating that the THPTS drug has a high degree of photodynamic inactivation. We then modulated incubation time, photosensitizer concentration and monitored the effect of serum on the THPTS activity. In doing so, we established the conditions to obtain the strongest bactericidal effect. Our results suggest that this new and highly pure synthetic compound should improve the efficiency of photodynamic therapy against multiresistant bacteria and has a significant potential for clinical applications in the treatment of nosocomial infections. © 2010 Schastak et al.
Biolitec AG | Date: 2010-06-23
The present invention provides pharmaceutical photosensitizer loaded nanoparticle formulations and their methods of preparation for photodynamic therapy, comprising a hydrophobic or hydrophilic photosensitizer, nanoparticulate calcium phosphate and in certain cases auxiliary reagents such as stabilizers. The calcium phosphate-based nanoparticle formulations of the present invention provide excellent storage stability and therapeutically effective amounts of photosensitizer for intravenous or topical administration. In a preferred embodiment, tetrapyrrole derivatives such as porphyrins, chlorins and bacteriochlorins, are the preferred hydrophobic photosensitizers to be formulated in calcium phosphate nanoparticle formulations for photodynamic tumor therapy. Additionally, pTPPP is a preferred hydrophilic photosensitizer for photodynamic tumor therapy. In another referred embodiment, hydrophilic cationic and anionic photosensitizers, especially those of the phenazinium, phenothiazinium and xanthenes series have been found to inactive pathogen bacteria and are the preferred photosensitizers to be formulated in calcium phosphate nanoparticle formulations for antibacterial photodynamic therapy. In another embodiment, photosensitizing nanoparticle formulations are useful to locate cells, tissues or bacteria by using fluorescence imaging methods.